 | | Vol. 23.19 – 6 June, 2022 |
| |
|
|
| Scientists outlined an approach for high-yield derivation of mesencephalic dopamine neurons that principally differed from alternative technologies by utilizing retinoic acid signaling, instead of WNT and FGF8 signaling, to specify mesencephalic fate.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators identified the autoimmune disease risk-associated locus and costimulatory molecule, CD226, as being highly expressed not only on effector T cells but also, interferon-γ producing peripheral regulatory T cells (Tregs).
[Frontiers in Immunology] |
|
|
|
| The authors administered approximately 20 million replication-incompetent VSV-G lentiviral particles carrying an anti-CD19CAR-2A-GFP transgene comprising either an FMC63 or 1D3 anti-CD19 binding domain, or a GFP-only control transgene, to wild-type C57BL/6 mice by tail vein infusion.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| 100% of B6 RIP-diphtheria toxin receptor mice rapidly became diabetic after a single dose of diphtheria toxin, and this was reversed indefinitely after transplantation with islets from congenic C57BL/6 mice.
[Scientific Reports] |
|
|
|
| In vitro preservation of pluronic F127-coated alginate-encapsulated canine adipose mesenchymal stem cell-derived insulin-producing cells (IPCs) was performed to verify ready-to-use IPCs.
[Scientific Reports] |
|
|
|
| Researchers found that tumor microenvironment factors, such as regulatory T cells and adenosine, downregulated type I interferon receptor IFNAR1 on CD8+ cytotoxic T lymphocytes.
[Nature Cancer] |
|
|
|
|
| Despite notable recent clinical and commercial successes, cell-based therapies continue to face numerous challenges that limit their widespread translation and commercialization.
[Nature Reviews Drug Discovery] |
|
|
|
| Scientists provide an overview of recent progress and current challenges of regulatory T cell-based therapies.
[Journal of Genetics and Genomics] |
|
|
|
|
| Abu Dhabi Stem Cells Center will begin the recruitment and enrollment of 45 patients in the Phase I/II study to evaluate the safety and efficacy of a pioneering new technology, extracorporeal photopheresis, which will be used in the treatment of multiple sclerosis.
[Abu Dhabi Stem Cells Center (Cision US, Inc.)] |
|
|
|
| Novartis announced the FDA has granted accelerated approval for Kymriah® for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
[Novartis] |
|
|
|
| The shortage of CAR-T therapy for multiple myeloma is creating a gut-wrenching dilemma for clinicians — one that they must debate each week at CAR-T myeloma programs like Yi Lin’s at the Mayo Clinic.
[STAT News] |
|
|
|
| After years of disappointment, gene-therapy research has undergone a renaissance, with several high-profile drug approvals and a string of promising clinical-trial results against devastating genetic diseases, including sickle-cell disease and some blood cancers.
[Nature News] |
|
|
|
|
| September 11 – 13, 2022
Lisbon, Portugal |
|
|
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Human Technopole – Milan, Italy |
|
|
|
| | China Medical University – Shenyang, China |
|
|
|
| | Stem Cell Network – Ottawa, Ontario, Canada |
|
|
|
| | Utrecht University – Utrecht, Netherlands |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
